Eloxatin is a registered trademark of sanofi aventis US. It is an antineoplastic that works by killing cancer cells and slowing tumor growth, is a cancer medication that interferes with the growth of cancer cells and slows their growth and spread in the body.
Following the court order dated April 22, 2010, Sun Pharma has appealed the court order and plans to litigate the matter before the US Court of Appeals for the Federal Circuit.
Sun Pharma believes that the bases for appeal are strong and plans to contest the entry of the Consent Judgement and Order. On receipt of a favorable judgement from the appellate court, Sun Pharma plans to reinitiate the sales of the product.